OR WAIT null SECS
May 31, 2023
Under the new MTA and Option License Agreement, Adcendo can nominate ADCs against two novel ADC targets, according to the press release.
The project is being coordinated by the recently formed not-for-profit CCRM Nordic AB and gathers engaged stakeholders to move the initiative forward.
May 30, 2023
Aragen and FAR Biotech will collaborate to advance a small-molecule neurodegeneration program.
The $87.5 million purchase grants Novartis rights to an investigational gene therapy program intended for treatment of cystinosis.
The guidance describes FDA’s current recommendations regarding adjusting for covariates in statistical analysis of randomized clinical trials.
The next Cannabis Science Conference Fall meeting is soliciting a call for abstracts.
May 26, 2023
Challenges to approval decisions have prompted FDA officials to reexamine of the role and composition of the agency’s many advisory committees and to explore options for change.
Paxlovid is not approved or authorized for use as a pre-exposure or post-exposure prophylaxis for prevention of COVID-19.
May 25, 2023
This agreement is intended to be executed and see the impact of any financial transfers by the fiscal year ending March 31, 2024.
FDA has approved the first topical gene therapy product for treating wounds in patients with dystrophic epidermolysis bullosa.